Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 4/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6001019 | 0.85 | PTGS1 (0.64) | PTGS1PTGS2PPARGCA2PTPN1 | |
| SCHEMBL6000980 | 0.78 | PTPN1 (0.63) | PTGS1PTGS2CA2ACLYPTPN1 | |
| SCHEMBL4976180 | 0.76 | PTGS1 (0.73) | PTGS1PTGS2CA2PGR | |
| SCHEMBL11278728 | 0.74 | CYSLTR2 (0.46) | PTGS1PTGS2CA2PTPN1CYSLTR2 | |
| SCHEMBL14689917 | 0.74 | PTGS1 (0.63) | PTGS1PTGS2CA2PTPN1CYSLTR2 | |
| SCHEMBL6000356 | 0.71 | PTPN1 (0.81) | CA2PTPN1PGR | |
| SCHEMBL18297880 | 0.71 | CYSLTR2 (0.50) | PTGS1PTGS2CA2PTPN1CYSLTR2 | |
| SCHEMBL6526296 | 0.70 | CYSLTR2 (0.58) | PTGS1PTGS2CA2PTPN1CYSLTR2 | |
| SCHEMBL6477002 | 0.70 | FABP3 (0.43) | CYSLTR2CYSLTR1 | |
| SCHEMBL4380993 | 0.70 | PTGS1 (1.00) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060281695-A1 | Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281695-A1 | Control of parasites in animals by N-[(phenyloxy)phenyl]-1,1,1-trifluoromethanesulfonamide and N-[(phenylsulfanyl)phenyl]-1,1,1-trifluoromethanesulfonamide derivatives | ELANE, CTRL, PIGO | PTGS1 296/4885PTGS2 1435/4885PPARG 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.